Mylan S.p.A.
Mylan S.p.A., a prominent player in the global pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and other key regions. Founded in 1961, Mylan has established itself as a leader in generic and specialty medications, focusing on improving access to high-quality healthcare solutions. The company offers a diverse portfolio of products, including generic drugs, over-the-counter medications, and complex generics, which are distinguished by their affordability and efficacy. Mylan's commitment to innovation and quality has earned it a strong market position, with notable achievements in expanding access to essential medicines worldwide. With a focus on patient-centric solutions, Mylan continues to play a vital role in the healthcare landscape, striving to meet the evolving needs of patients and healthcare providers alike.
DitchCarbon Score
How does Mylan S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mylan S.p.A.'s score of 53 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mylan S.p.A., headquartered in Italy, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Viatris Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. As of now, Mylan S.p.A. has not outlined specific reduction targets or initiatives in its own documentation. However, it is important to note that Viatris Inc. has established various climate commitments, which may influence Mylan's sustainability strategies. These commitments include participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded to Mylan S.p.A. from Viatris Inc. at a corporate family level. While Mylan S.p.A. has not disclosed its own emissions or reduction targets, the overarching goals set by Viatris Inc. may guide its climate action efforts in the future. The absence of specific data highlights the need for further transparency and commitment to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mylan S.p.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
